

Special Issue

Recent Advances in Personalised Gastrointestinal Cancer Treatments

Message from the Guest Editors

Recent advances in our ability to understand and manipulate cancer have led to a plethora of new avenues for personalised medicine in gastrointestinal cancer treatment.

Such advances include the use of sophisticated 3D ex vivo models of tumour epithelium (organoids), their co-culture with immune and stromal cells, the development of complex genetically engineered mouse models of cancer, and the ability to unpack cell–cell interactions on slide using multiplex imaging platforms. Together, these models can be used to explore the efficacy of novel drug delivery systems, impact of chemotherapies, radiotherapy, gene therapy, and cell therapies.

This Special Issue aims to collect advanced studies of personalised medicine potential in the treatment of gastrointestinal cancers. We welcome the submission of original research papers as well as review articles, with the aim of building a unique bank of knowledge which will be extremely useful to those working in the field.

gastrointestinal cancer
genetics
cell biology
drug delivery
personalised medicine

Guest Editors

Dr. Eoghan Joseph Mulholland

Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Dr, Headington, Oxford OX3 7BN, UK

Dr. Emma McErlean

School of Pharmacy, Queen's University Belfast, Belfast, UK

Deadline for manuscript submissions

closed (31 August 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/135992

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).